RecruitingPhase 2NCT06450925

Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.

A Randomized Double Blinded Trial of Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.


Sponsor

Children's Hospital Medical Center, Cincinnati

Enrollment

190 participants

Start Date

Mar 25, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The investigators hypothesize that single oral high dose supplementation with vitamin A will reduce the incidence of moderate-severe chronic graft-versus-host disease (GVHD) compared with placebo.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo and a drug called Vitamin A for people with graft vs host disease, vitamin a deficiency, and other related conditions. The study is currently recruiting participants at 3 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVitamin A

Enrolled subjects will receive one observed oral vitamin A dose, prior to their HSCT, in the outpatient clinic or inpatient Bone Marrow Transplant (BMT) floor.

OTHERPlacebo

Placebo pills containing microcrystalline cellulose will be dispensed in patients who are randomized to the placebo arm.


Locations(3)

Moffitt Cancer Center

Tampa, Florida, United States

Roswell Park Comprehensive Cancer Center

Buffalo, New York, United States

The Ohio State University

Columbus, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06450925


Related Trials